{
    "Trade/Device Name(s)": [
        "HbA1c Advanced"
    ],
    "Submitter Information": "Beckman Coulter Ireland Inc.",
    "510(k) Number": "K182651",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151321"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "January 16, 2019",
    "Summary Letter Received Date": "September 24, 2018",
    "Submission Date": "January 15, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system",
        "Assay Glycosylated Hemoglobin"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c",
        "Total Hemoglobin"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2 EDTA tube",
        "K3 EDTA tube",
        "Sodium Heparin tube",
        "Lithium Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxC 700 AU Clinical Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Turbidimetric inhibition immunoassay",
        "Colorimetric method"
    ],
    "Methodologies": [
        "Immunoassay",
        "Colorimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for HbA1c Advanced assay using turbidimetric inhibition immunoassay on the DxC 700 AU Clinical Chemistry Analyzer for quantifying hemoglobin A1c in venous whole blood.",
    "Indications for Use Summary": "Quantitative determination of mmol/mol HbA1c (IFCC) and % HbA1c (DCCT/NGSP) concentration in human venous whole blood to aid diagnosis and monitoring of diabetes mellitus and identify patients at risk for developing diabetes mellitus.",
    "fda_folder": "Clinical Chemistry"
}